Welcome to our dedicated page for Ernexa SEC filings (Ticker: ERNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ernexa Therapeutics Inc. (NASDAQ: ERNA) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Ernexa’s development-stage biotechnology business, which focuses on iPSC-derived iMSC cell therapies for advanced cancer and autoimmune disease.
Through this page, readers can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand Ernexa’s financial position, operating expenses, research and development priorities, and risk disclosures typical of early-stage biotechnology companies. Current reports on Form 8-K capture material events, such as the disclosed change in Ernexa’s independent registered public accounting firm and references to going concern considerations and internal control matters.
For those following governance and ownership, proxy statements and related filings can provide information on board structure and executive compensation, while beneficial ownership reports and Form 4 filings allow tracking of insider transactions by directors, officers, and significant shareholders, when available. Together, these documents help investors and analysts evaluate how Ernexa manages its cell therapy programs, capital resources, and corporate oversight.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain complex sections in plain language, and draw attention to items such as going concern notes, material weaknesses in internal control, or important changes in auditors. Real-time updates from EDGAR ensure that new Ernexa filings appear promptly, while AI-generated overviews of 10-Ks, 10-Qs, 8-Ks, and Form 4 submissions can save time for users seeking to understand the regulatory record behind the ERNA ticker.
Ernexa Therapeutics Inc. reported Q3 2025 results with a net loss of $1.24 million, a sharp improvement from a loss of $26.60 million a year ago. Year‑to‑date net loss was $12.58 million versus $38.78 million in 2024. There was no revenue in Q3 2025, compared with $0.49 million in Q3 2024, reflecting the prior assignment of its customer contract to Factor Bioscience.
Operating expenses were stable to lower: research and development was $1.04 million (vs. $1.00 million), while general and administrative fell to $0.96 million (vs. $3.38 million), aided by the absence of prior-year lease and professional fee items. Other income included a $0.73 million gain from writing off time‑barred payables. Year‑to‑date other expense was driven by a $5.85 million non‑cash forward sales contract expense tied to a 2025 private placement.
Cash was $3.05 million as of September 30, 2025, up from $1.73 million at year‑end, after $7.20 million of gross proceeds from common stock and pre‑funded warrant sales in 2025 and repayment of $2.3 million promissory notes. The company used $5.87 million in operating cash year‑to‑date and states there is substantial doubt about its ability to continue as a going concern without additional capital. A 1‑for‑15 reverse stock split became effective on June 12, 2025; 7,848,889 common shares were outstanding as of November 7, 2025.
IAF, LLC reports it currently beneficially owns 315,779 shares of Ernexa Therapeutics Inc. common stock, representing 4.1% of the outstanding class based on 7,670,889 shares reported by the issuer. This Amendment No. 3 updates prior Schedule 13G filings and indicates the reporting person has ceased to own more than 5% of the company, making this an "exit filing." The filing shows all 315,779 shares are held with sole voting and sole dispositive power and confirms the holder does not report ownership on behalf of others or as part of a group.
Ernexa Therapeutics is a preclinical synthetic allogeneic iMSC therapy company developing ERNA-101 (IL-7/IL-15–secreting) for oncology and ERNA-201 for inflammatory disorders. Management expects to complete IND-enabling studies and submit an IND in 2026 with a planned Phase I investigator-sponsored trial in the second half of 2026.
Financially, the company reported $4.3 million in cash and an accumulated deficit of $242.9 million. Net loss was $3.1 million for the quarter and $11.3 million for the six months, which includes a $5.8 million non-cash forward sales contract expense. Ernexa raised approximately $7.2 million gross from a private placement, completed a 1-for-15 reverse stock split and increased authorized common shares to 150 million. Management disclosed substantial doubt aboutgoing concern and stated additional financing will be required. Stockholders' equity was $4.4 million at period end and the company reports compliance with Nasdaq continued listing standards.
Ernexa Therapeutics Inc. (CIK 0000748592) has received SEC clearance for its shelf registration. The company’s Form S-3 registration statement (File No. 333-287954) was declared effective on 18 June 2025 at 4:30 p.m. Eastern Time. A Form S-3 allows eligible issuers to register multiple classes of securities and later access capital markets quickly through takedowns without filing a new registration with each offering.
While the filing itself contains no financial metrics or details on the amount or type of securities that may be offered, effectiveness formally authorises Ernexa to issue securities when market conditions are favourable. Investors should monitor subsequent prospectus supplements for specific terms, such as share counts, pricing, and potential dilution.
FAQ
What is the current stock price of Ernexa (ERNA)?
What is the market cap of Ernexa (ERNA)?
